Research

Research

ZHAO Zijian

School

School of Biomedical and Pharmaceutical Sciences

Title

Professor, PhD supervisor, Master supervisor

Research Interests

research on applied chemistry, biopharmaceutical and natural product

Home Page

https://yzw.gdut.edu.cn/info/1093/1297.htm

Contacts

Tel:18027330698, Email:azzhao@gdut.edu.cn

Personal Introduction

Dr. Zhao is a distinguished professor of Hundred Talents Program at Guangdong University of Technology, a national distinguished expert, and a Chief Scientist of the “973” Major Research Program of the Ministry of Science and Technology,the first batch of distinguished professor candidate in Jiangsu Province, the leader of the innovation and entrepreneurship team of the Pearl River Talent Program in Guangdong Province. After receiving a Ph.D. degree in biochemistry and molecular biology from the University of Southern California, he engaged in drug development research in the Department of Pharmacology, Seattle Medical College, University of Washington, USA. In 2000, he served as tenured professor in the Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine.Dr. Zhao’s research projects have been supported by the Chinese Ministry of Science and Technology, the Natural Science Foundation, the American NIH, the American Diabetes Association, the American Heart Association, and many others. His outcomes have been published in Nature-Medicine Nature-Neuroscience, PNAS, JCI, Diabetes and other top and professional journals as the first and corresponding author. Over the years, Dr. Zhao has paid attention to the clinical application of research results, some of which have been declared and obtained international patent protection, and some are already being declared for clinical trials.

Education

September 1980-July 1984: Master of Science, Department of Chemistry, Peking University

September 1984-July 1987: Ph.D., Department of Chemistry, Peking University

September 1987-July 1992: Ph.D., Department of Biochemistry, University of Southern California, USA

Work Experience

September 1994 to August 1997, Lecturer, Washington State University, USA

September 1997 to August 1999, Tenured Professor, University of Washington, USA

September 2000 to August 2010, Professor, University of Pittsburgh, USA, USA

September 2010 to October 2015, Professor, Nanjing Medical University, China

November 2015 to August 2016, Professor, South China University of Technology, China

September 2016 to present, Professor, Guangdong University of Technology

Part-time Academic Job

N/A

Main Honor

National Distinguished Expert

Career & Development Award and Research Award granted by American Diabetes Association

Chief Scientist of "973" Project of Ministry of Science and Technology

Leader of the Innovation and Entrepreneurship Team of the Pearl River Talent Program in Guangdong Province

Leading talents for entrepreneurship in Guangzhou

Outstanding Talents in Guangzhou Development Zone

Main Achievements

[1] Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X,Zhao AZ*. (2017) ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J Clin Invest. 2017 May 1;127(5):1757-1771.

[2] Cheng, Lixian,Shi, Hui,Jin, Yan,Li, Xiaoxi,Pan, Jinshun,Lai, Yimei,Lin, Yan,Jin, Ya,Roy, Gaurab,Zhao, Allan*,Li, Fanghong*. (2016) Adiponect in Deficiency Leads to Female Subfertility and Ovarian Dysfunctions in Mice.,Endocrinology,157(12):4875~4887.

[3] Li, Jie,Wei, Dong,McCrory, Mark A,Szalai, Alexander J,Yang, Gangyi,Li, Ling,Li, Fanghong(*),Zhao, Allan Z *. (2016) Human C-reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in the CNS.,Biochem J,473(9): 1215~1224.

[4] Zhou S, Zhao Z, Lin Y, Gong S, Li F, Pan J, Li X, Gao Z,Zhao AZ*. (2016) Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system. Cancer Biol Ther, 17(7):732-40.

[5] Pan J, Cheng L, Bi X, Zhang X, Liu S, Bai X, Li F,Zhao AZ*. (2015) Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production. Sci Rep. 5:14958.

[6] Wei, D., Li, J., Shen, MD, Jia,W, Tian,H., Dai,Y., andZhao, AZ *. (2010) Cellular Production of n-3 PUFAs and Reduciton of n-6/n-3 ratios in the Pancreatic b-cells and Islets Enhance Insulin Secretion and Confer Protection against Cytokine-induced Cell Death. Diabetes. 59: 471-478.

[7] Cong L, Gasser J, Zhao J, Yang B, Li F,Zhao AZ *.(2007) Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95- Endocr Relat Cancer. 14(3): 713-20.

[8] Cong L, Chen K, Li J, Gao P, Li Q, Mi S, Wu X,Zhao AZ *. (2007) Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes. Biochem J. 403(3): 519-25.

[9] Chen, K., Li, FH, Li, J., Cai, H., Strom, S., Bisello, A., Friedman-Einat, M., Kelley, DE, McCroy, M., Szalai, A.,Zhao, AZ *. (2006) Induction of Leptin Resistance through Direct Interaction ofC-Reactive Protein with Leptin. Nature Medicine 12: 425-432.

[10] Li, J, Li, F, andZhao, AZ *. (2006) Inflammation and Leptin,Drug Discovery Today: Disease Mechanisms 3 (3): 387-393.

[11] Huan, J.N., Li, J., Han, Y.P., Chen, K., Wu, N., andZhao, A.Z*. (2003) Adipocyte-Selective Reduction of the Leptin Receptors Induced by Antisense-RNA Leads to Increased Adiposity, Dyslipidemia and Insulin Resistance. J. Biol. Chem. 278: 45638-45650.

[12]Zhao, A.Z., Huan, J.N. and Sahu, A. (2002) Requirement of a PI3K-PDE3B-cAMP Pathway for the Satiety Function of Leptin in the Hypothalamus. Nature Neuroscience 5:727-728.

[13]Zhao, A.Z., Shinohara, M., Huang, D., Eldar-Finkelman, H., Krebs, E.G., Beavo, J.A. and Bornfeldt, K.E. (2000) Leptin Antagonizes the Action of Glucagon by Activating Phosphodiesterase 3B in Primary Hepatocytes. J. Biol. Chem. 275:11348-11354.

[14]Zhao, A.Z., Bornfeldt, K.E., and Beavo, JA. (1998) Leptin Inhibition of Insulin Secretion through Activation of Phosphodiesterase 3B.J. Clinc. Inves. 102: 869-873.

[15]Zhao, A.Z., Zhao, H., Teague, J., Fujimoto, W., and Beavo, J.A. (1997) Attenuation of Insulin Secretion by Insulin-like Growth Factor 1 Is Mediated through Activation of Phosphodiesterase 3B. Proc. Natl. Acad. U.S.A. 94: 3223-3228. Patents authorized in recent years:

1 genetically engineered battery for treatment of break cage, method for constructing the battery, and applications threeo, invention patent, U.S.A., patent No. 14766558, date of announcement 2017-09-13

2 Application of an attenuated Salmonella typorium invention patent, USA, patent No. 9439934, date of authorization announcement: August 24, 2016

3 genetically engineered bacterium for treatment of break cage, patent for invention, Australia, patent No.: 2014223112, date of announcement: February 3, 2017

4 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of drugs for the treatment of pancreatic cancer, invention patent, China, patent No.: zl201310688936.3, date of authorization announcement: February 24, 2016

5. A genetically engineered bacterium for the treatment of breast cancer and its construction method and application, invention patent, China, patent No.: zl201310062253.7, authorized announcement date: December 31, 2014

6 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of prostate cancer drugs, patent for invention, China, patent No.: zl201410183149.8, date of authorization announcement: August 8, 2018

7 compositions for blocking the innovation effect of invention patent, U.S.A., patent No. 7629315, announcement date of authorization: December 8, 2009

Patent pending:

1. Application of genetically engineered bacteria vnp2009-m in the preparation of lung cancer prevention and treatment drugs, invention patent, Hong Kong, China, patent application No. 18100076.7, application date: January 3, 2018, preliminary examination stage

2. Application of genetically engineered bacteria vnp2009-m in the preparation of drugs for the treatment of malignant sarcoma, invention patent, Hong Kong, China, patent application No. 18101397.7, application date: January 29, 2018, preliminary examination stage

3. Application of genetically engineered bacteria vnp2009-m in the preparation of drugs for prevention and treatment of cancer metastasis, invention patent, China, patent application No. 2016100812709 application date: February 5, 2016, substantive examination stage

Main Projects

1. Research on the molecular relationship between lipid metabolism disorder and spermatogenesis disorder, national key basic research and development plan, Zhao Zijian, 2013-20172100 million

2. Research and development of biological anticancer drug sgn1 in the treatment of advanced cancer and phase 1 and phase 2 clinical trials. Guangdong Provincial Department of science and technology, Zhujiang talent plan to introduce innovation and entrepreneurship team, Zhao Zijian, 2016-20222 million

3. Regulatory mechanism of the interaction between leptin and C-reactive protein (CRP) on body weight and glycolipid metabolism, National Natural Science Foundation of China, Zhao Zijian, 2016-20202.75 million

Research Team

The team has a number of teachers graduated from key universities, as well as PhD students who can helpsupervise the research work of graduate students.